之前和之后的治疗期间，使用简短的精神病评定量表(BPRS)，临床症状进行评估。
Clinical symptoms were assessed before and after the treatment period, using the Brief Psychiatry Rating Scale (BPRS).
采用日常生活能力量表（ADL）对两组患者生活能力情况进行评定，并用简明精神病评定量表（BPRS）观察两组患者的预后。
With activities of daily living (ADL), capable of living conditions of the two groups were assessed with the Brief Psychiatric Rating Scale (BPRS) the prognosis of patients were observed.
方法用奥氮平治疗首发精神分裂症32例，疗程8周；用简明精神病评定量表(BPRS)和副反应量表(TESS)评定疗效及副反应。
Method: 32 patients with first episode schizophrenia were treated with olanzapine for 8 weeks, and assessed with BPRS and TESS for the efficacy and safety.
疗效和不良反应分别用简明精神病评定量表（BPRS）和副反应量表（TESS）进行评定，并测定治疗第1，2，4，6周的稳态血药浓度。
Therapeutic efficacy was measured by BPRS and the adverse reaction was rated by TESS. Steady serum level was monitored within 1, 2, 4, 6 week.
评定工具用简明精神病评定量表(BPRS)、住院精神病人康复疗效评定量表(IPROS)和自我效能感量表(GESE)进行对照评定分析。
The patients were assessed by brief psychiatric rating scale (BPRS), inpatient psychiatric rehabilitation outcome scale (IPROS) and general self-efficacy scale (GESE).
方法对33例接受氯氮平治疗的精神分裂症患者进行定期门诊随访3年，并以简明精神病评定量表(BPRS)、副反应量表(TESS)进行疗效和副反应评定。
Methods 33 patients were accepted clozapine treatment only and followed 3 years by regular clinic visits. Using the BPRS, TESS to evaluate the efficacy.
采用异常不自主运动量表（AIMS）和简明精神病评定量表（BPRS）及副反应量表（TESS）在治疗前及治疗后1、2、4、6周末分别评定疗效及不良反应。
The efficacy and safety were assessed with AIMS, BPRS and TESS at the end of week 1,2,4 and 6.
采用异常不自主运动量表（AIMS）和简明精神病评定量表（BPRS）及副反应量表（TESS）在治疗前及治疗后1、2、4、6周末分别评定疗效及不良反应。
The efficacy and safety were assessed with AIMS, BPRS and TESS at the end of week 1,2,4 and 6.
应用推荐